To test the hypothesis that albiglutide exerts a positive inotropic effect in the human heart via GLP-1R.
Approach:
Study Design: Measured contractility in paced human atrial preparations from adult patients undergoing surgery for severe coronary heart disease.
Experimental Conditions: Evaluated the effects of albiglutide at various concentrations and in the presence of other pharmacological agents.
Key Findings:
Albiglutide exhibited a time- and concentration-dependent positive inotropic effect starting at 10 nM and peaking at 100 nM.
The positive inotropic effect was enhanced by cilostamide and reduced by a specific protein kinase inhibitor.
Albiglutide's effects were not reversed by propranolol and were less potent than isoprenaline.
In murine atrial preparations, albiglutide did not increase force of contraction or beating rate.
Interpretation:
Albiglutide increases the force of contraction in human atrial preparations via GLP-1R stimulation and cAMP-dependent phosphorylation, acting as a partial GLP-1R agonist.
Limitations:
The study was limited to human atrial preparations and did not include a broader range of cardiac tissues.
Effects observed in human atrial preparations may not directly translate to in vivo conditions.
Conclusion:
Albiglutide's positive inotropic effects suggest potential differences in clinical side effects compared to full GLP-1R agonists.
